Dr Sophie Kellaway has been awarded a Vivo biobank grant by CCLG to determine whether a drug already on the market for asthma could prevent relapse of t(8;21) AML. This research follows on from pioneering work published in Nature Communications 2 years ago showing that t(8;21) stem cells hijack the IL-5 pathway to grow. The question is now whether an antibody called benralizumab, which targets the immune system to cells with the IL-5 receptor, can help the immune system find and kill AML stem cells too.
Read more about the award and the special named funds which contribute: https://www.cclg.org.uk/our-research/our-research-projects/using-asthma-medicine-harness-immune-system-and-prevent-childhood-leukaemia-returning and https://www.cclg.org.uk/news-updates/cclg-special-named-funds-support-new-collaboration-with-vivo-biobank